/ATOS
ATOS Stock - Atossa Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$0.73+3.82%
+$0.03 (+3.82%) • Dec 19
67
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.21
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.82
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+583.9%upside
Target: $5.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ATOS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.72 – $0.74
TARGET (TP)$5.00
STOP LOSS$0.67
RISK/REWARD1:69.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.95
52W High$1.29
52W Low$0.55
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-27,621,000 | $-31,377,000 | $-27,691,000 | $-20,521,000 | $-14,607,000 |
| Net Income | $-25,504,000 | $-30,094,000 | $-26,960,000 | $-20,606,000 | $-17,828,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.20 | $-0.24 | $-0.21 | $-0.18 | $-1.97 |
Company Overview
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ATOSBeat Rate
42%
Last 19 quarters
Avg Surprise
-12.0%
EPS vs Estimate
Beats / Misses
8/7
4 met exactly
Latest EPS
$-0.07
Q4 2025
EPS Surprise History
Q1 24
-50.0%
$-0.09vs$-0.06
Q2 24
-20.0%
$-0.06vs$-0.05
Q3 24
0.0%
$-0.05vs$-0.05
Q4 24
+16.7%
$-0.05vs$-0.06
Q1 25
+16.7%
$-0.05vs$-0.06
Q2 25
+16.7%
$-0.05vs$-0.06
Q3 25
-16.7%
$-0.07vs$-0.06
Q4 25
0.0%
$-0.07vs$-0.07
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 24, 2026 | $-0.07 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.07 | $-0.07 | 0.0% | = MET |
Q3 2025 | Aug 12, 2025 | $-0.06 | $-0.07 | -16.7% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.06 | $-0.05 | +16.7% | ✓ BEAT |
Q1 2025 | Mar 25, 2025 | $-0.06 | $-0.05 | +16.7% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.06 | $-0.05 | +16.7% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-0.05 | $-0.05 | 0.0% | = MET |
Q2 2024 | Apr 1, 2024 | $-0.05 | $-0.06 | -20.0% | ✗ MISS |
Q1 2024 | Mar 27, 2024 | $-0.06 | $-0.09 | -50.0% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-0.07 | $-0.05 | +28.6% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.06 | $-0.06 | 0.0% | = MET |
Q2 2023 | May 15, 2023 | $-0.06 | $-0.05 | +16.7% | ✓ BEAT |
Q1 2023 | Mar 22, 2023 | $0.06 | $-0.06 | -200.0% | ✗ MISS |
Q4 2022 | Nov 7, 2022 | $-0.06 | $-0.06 | 0.0% | = MET |
Q3 2022 | Aug 8, 2022 | $-0.06 | $-0.05 | +16.7% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $-0.05 | $-0.04 | +20.0% | ✓ BEAT |
Q1 2022 | Feb 28, 2022 | $-0.04 | $-0.04 | -11.1% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-0.04 | $-0.04 | -11.1% | ✗ MISS |
Q3 2021 | Aug 13, 2021 | $-0.04 | $-0.06 | -71.4% | ✗ MISS |
Q2 2021 | May 14, 2021 | $-0.05 | $-0.04 | +20.0% | ✓ BEAT |
Latest News
Atossa Therapeutics Presents Four Clinical Trial Updates On (Z)-Endoxifen At SABCS
➖ NeutralBenzinga•Dec 15, 2025, 01:03 PM
Atossa Therapeutics shares are trading higher after the company received FDA Rare Pediatric Disease Designation for (Z)-endoxifen in Duchenne muscular dystrophy.
📈 PositiveBenzinga•Dec 11, 2025, 01:12 PM
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation For (Z)-Endoxifen In Duchenne Muscular Dystrophy
📈 PositiveBenzinga•Dec 11, 2025, 01:11 PM
Atossa Therapeutics Secures U.S. Patent for Methods of Making And Using Endoxifen
📈 PositiveBenzinga•Dec 9, 2025, 01:06 PM
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $8
📈 PositiveBenzinga•Dec 8, 2025, 10:35 AM
Atossa Therapeutics Completes Type C Meeting With FDA To Review Strategy For Advancing (Z)-Endoxifen
📈 PositiveBenzinga•Dec 4, 2025, 01:07 PM
Insilico Medicine And Atossa Therapeutics Announce Publication Of Joint Study Evaluating Potential Of (Z)-Endoxifen For Glioblastoma Multiforme
➖ NeutralBenzinga•Dec 2, 2025, 01:20 PM
Atossa Highlights (Z)-Endoxifen's Multi-Pathway Potential In Duchenne Muscular Dystrophy And Carrier-Associated Pathologies
📈 PositiveBenzinga•Nov 17, 2025, 02:11 PM
Atossa Therapeutics Q3 EPS $(0.07), Inline
➖ NeutralBenzinga•Nov 12, 2025, 01:18 PM
Atossa Therapeutics To Present Four Abstracts On (Z)-Endoxifen At San Antonio Breast Cancer Symposium
📈 PositiveBenzinga•Nov 6, 2025, 01:31 PM
Atossa Highlights Enrollment Progress And Biomarker Strategy For RECAST Trial, Aiming to De-Risk Development Of (Z)-Endoxifen For Ductal Carcinoma In Situ
📈 PositiveBenzinga•Oct 21, 2025, 12:17 PM
Atossa Therapeutics Appoints Mark Daniel As CFO
➖ NeutralBenzinga•Oct 14, 2025, 12:15 PM
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $7.75
📈 PositiveBenzinga•Sep 22, 2025, 09:28 AM
Atossa Therapeutics Announces It Has Requested A Type C Meeting With The FDA To Discuss A Regulatory Strategy To Accelerate The Development Of Low-Dose Endoxifen For Reducing Breast Cancer Risk
📈 PositiveBenzinga•Sep 8, 2025, 12:36 PM
Atossa Therapeutics Selects PSI To Manage FDA-Guided (Z)-Endoxifen Dose-Ranging Study In Metastatic Breast Cancer Ahead Of Phase 3
📈 PositiveBenzinga•Aug 20, 2025, 12:31 PM
Atossa wins U.S. patent related to multiple formulation of lead asset
📈 PositiveSeeking Alpha•Apr 30, 2025, 06:40 PM
Frequently Asked Questions about ATOS
What is ATOS's current stock price?
Atossa Therapeutics, Inc. (ATOS) is currently trading at $0.73 per share. The stock has moved +3.82% today.
What is the analyst price target for ATOS?
The average analyst price target for ATOS is $5.00, based on 1 analyst.
What sector is Atossa Therapeutics, Inc. in?
Atossa Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ATOS's market cap?
Atossa Therapeutics, Inc. has a market capitalization of $0.09 billion, making it a small-cap company.
Does ATOS pay dividends?
No, Atossa Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCGTX
Cognition Therapeutics, Inc.
$1.54
Mkt Cap: $0.1B
CLNN
Clene Inc.
$6.68
Mkt Cap: $0.1B
COYA
Coya Therapeutics, Inc.
$5.49
Mkt Cap: $0.1B
GLSI
Greenwich LifeSciences, Inc.
$13.01
Mkt Cap: $0.2B
IMMX
Immix Biopharma, Inc.
$5.72
Mkt Cap: $0.2B
ONCY
Oncolytics Biotech Inc.
$1.01
Mkt Cap: $0.1B
SRZN
Surrozen, Inc.
$21.76
Mkt Cap: $0.2B
TIL
Instil Bio, Inc.
$11.27
Mkt Cap: $0.1B
TVGN
Tevogen Bio Holdings Inc.
$0.38
Mkt Cap: $0.1B
WHWK
Whitehawk Therapeutics Inc
$2.56
Mkt Cap: $0.1B
Explore stocks similar to ATOS for comparison